Psilocybin Assisted-Psychotherapy

Many public and commercial psychedelic enterprises are working on producing synthetic and mushroom drugs, and an increasing number of them are interested in psychedelic-assisted therapy.

The availability of psilocybin-assisted therapy will increase as a result of these improvements, though the cost barriers to entry are not yet established. However, psilocybin-assisted treatment may soon gain acceptance as a legitimate subfield of psychotherapy.

Intake of psilocybin is a component of psilocybin-assisted therapy, which aims to promote healing and transformation while exploring a particular, predetermined intention. The three separate therapy phases of preparation, the acute psychedelic experience, and integration are frequently mentioned by researchers and physicians. The non-psychedelic components of this strategy are critical to its efficacy and security.

Typically, there is a preparation phase in which the patient and therapist get to know one another, and form a trusting relationship.

  • During the session, the patient lies down in a specially designed room, with a comfortable bed or mat. They should feel at ease in the environment

  • Often, a specially curated music playlist will be listened to which is designed to heighten the inward journey, while wearing a comfortable eye mask, similar to one for sleeping.

  • Most patients begin to feel the significant effects approximately 30-45 minutes after receiving their dose, which typically lasts for 3-4 hours, followed by 1-2 hours of “come down”. A trained therapist remains present at all times throughout this session.

  • Following this time, sometimes referred to as a “journey”, patients are encouraged to discuss their experience. With guidance from their therapist, the goal is to identify insights that may create lasting positive change with emotional or behavioral patterns.

Image/Info Provided By MindMedicineAustralia.org.au,https://www.psilocybin.org/

SykoActive

Graham Krutch, also known as 'Gram Kracker,' is the founder and CEO of SykoActive Non-Profit Association, boasting over two decades of experience in the industry of medicinal plants and psychedelic substances. His expertise extends from cultivation to patient consultation, primarily focusing on cannabis and psilocybin, alongside notable advancements in the hemp and CBD sector.

Under Graham's guidance, SykoActive investigates and advocates for the therapeutic uses of psychedelic plant medicines. He is committed to informing the public about secure alternative treatments and tackling the worldwide mental health dilemma.

Beyond his involvement in the psychedelic realm, Graham possesses a varied skill set in event marketing and product management. His efforts have been instrumental in the prosperity of leading convenience stores, and he shines in team leadership, strategic planning, and project management. As a fervent proponent of Applied AI Science and proficient in AI research and technological tools, he adeptly merges a customer-centric approach with an acute awareness of time constraints.

https://www.sykoactive.com
Previous
Previous

Investigating The Therapeutic Potential of Psychedelics

Next
Next

Father Of A Nation, Wisdom For The World